ClinicalTrials.gov
public full text
Public Domain
A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects
Debio 1450 is metabolised mainly by CYP3A4, therefore inhibitors of CYP3A4 have the potential to raise Debio 1450 plasma concentrations. Hence, it is important to determine the effect of CYP3A4 inhibition by itraconazole on the Pharmacokinetics of Debio 1450.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers#314368
- Síntese, Caracterização e Avaliação da Atividade Anticancerígena de Novos Híbridos de 1,2,3-Triazol e Ftalimid#465803
- Dental antibiotic stewardship: study protocol for developing international consensus on a core outcome set#983957
- Study of Debio 1450 for Bacterial Skin Infections#343863
- In vitro exposure to the agricultural triazole tebuconazole selects for fluconazole cross-resistance and echinocandin tolerance in Candidozyma auris.#427816
Record · ID 1073544
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive